The path from lab to market is difficult. Life science startups must fund research, legal and regulatory activities. These are often costly, lengthy and complex, requiring external resources over which the startup has little if any bargaining power. Attention and resources are thus understandably diverted from the other risk categories of concern to financial investors – Market, Management and Money. Financial investors may lose faith. BPV brings balance to this equation.
BPV focuses on the ‘transfer’ in life science tech transfer, also known as commercialization of translational research. We partner with scientists, investors and IP owners starting or restarting life science ventures.
BPV likes ethical ventures with breakthrough innovations that have the potential to make money and improve happiness by bringing good into the world. BPV integrates humanitarian and commercial missions to catalyze investment returns to financial investors and philanthropies.
BPV is a relentlessly steadfast, supportive partner to ventures that fit our profile. We are adept at salvaging and leveraging value from previous direct and indirect investments by investors and research institutions.
BPV concentrates on risk mitigation. We find ways to transform constrained capital into an asset. We stay focused on accelerating the path to revenue by integrating clinical development with brand-building, marketing, sales and operations. Our goals are to create healthy work environments, improve the odds of delivering forecast returns, accelerate enterprise value, reduce time to exit and increase exit value.